title: [Thrombophilic syndrome associated to phenotypic resistance to activated protein C in postmenopausal women].
abstract: OBJECTIVE
  Hormone replacement therapy (HRT) may reduce the risk of cardiovascular events in healthy postmenopausal women. However recent studies suggest a 2-4 fold increased risk of idiopathic venous thromboembolism (VTE) among users of HRT. Our aim was to evaluate the overall effect of HRT on hemostatic variables probably related to increased VTE risk reported in epidemiological studies.
  
  
  METHODS
  Therefore, 100 healthy postmenopausal women aged 45-60 years divided into 50 HRT non-users and 50 HRT users were examined. The authors assayed on the automated coagulometer ACL7000 (Instrumentation Laboratory, Milan) the procoagulant proteins: factor VIII (VIII:C) and factor VII (VII:C); the natural anticoagulant proteins: antithrombin (ATIII), protein C (PC), protein S (PS) and the resistance to anticoagulant action of activated protein C (APC-Resistance). The free tissue factor pathway inhibitor (TFPI) was measured with an ELISA method (Diagnostica Stagò; France, Roche). The in vivo coagulation and fibrinolysis activation was evaluated by the assays of prothrombin fragment 1+2 (F1+2) and plasmin- antiplasmin complexes (PAP) using ELISA techniques.
  
  
  RESULTS
  Increased levels of FVIII:C and FVII:C were observed in HRT users and HRT non-users women compared to controls (FVIII:C= 126+/-58%, 120+/-59% vs 85+/-15% p=0.0001; FVII: C 113+/-23%, 103+/-19% vs 90+/-16% p=0.0001). The activation peptides were significantly different compared to those found in control subjects; higher values were observed in HRT users compared to HRT non-users (F1+2=1.11+/-0.44 nM, 077+/-0.31 nM vs 0.45+/-0.35 p=0.00001; P-AP= 606+/-406 ng/ml, 514+/-205 ng/ml vs 235+/-59 p=0.0001). The ATIII and the PC were similar among the 3 different groups of subjects, but reduced levels of PS were observed in HRT users (PS 93+/-23%, 105+/-22% vs 109+/-12 p=0.0001). The mean normalized APC sensitivity ratio (APC-SR) was lower in the two populations of women as compared with that of controls (nAPC-SR 1.02+/-0.7, 1.02+/-0.8 vs 1.1+/-25 p=0.02). The values of free TFPI were reduced in HRT users compared to HRT non-users (9.1+/-1.9 ng/ml, 10.1+/-2.3 ng/ml vs 4.6+/-1.5 ng/ml p<0.0001).
  
  
  CONCLUSIONS
  HRT appears to be associated to a shift in the procoagulant-anticoagulant balance towards a procoagulant state. The changes in hemostatic system could explain the increased risk of VTE in healthy postmenopausal women during HRT, nevertheless this risk could be higher in women known to have a congenital or acquired thrombophilic state.
authors.affiliation: Dipartimento di Scienze Ginecologiche, Ostetriche e della Riproduzione, Laboratorio di Emostasi e Trombosi, II Università degli Studi di Napoli, Naples, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Caserta
authors.forename: R
authors.initials: R
authors.lastname: Caserta
authors.forename: M
authors.initials: M
authors.lastname: Torella
authors.forename: F
authors.initials: F
authors.lastname: Perricone
authors.forename: E
authors.initials: E
authors.lastname: Nesti
authors.forename: M
authors.initials: M
authors.lastname: Sessa
authors.forename: A
authors.initials: A
authors.lastname: Tagliaferri
authors.forename: F
authors.initials: F
authors.lastname: De Francesco
authors.forename: D
authors.initials: D
authors.lastname: De Lucia
authors.forename: S
authors.initials: S
authors.lastname: Panariello
mesh_terms: D020016:Activated Protein C Resistance / Q000139:chemically induced* / Q000235:genetics; D000328:Adult; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010641:Phenotype; D017698:Postmenopause; D011372:Progestins / Q000009:adverse effects*; D013577:Syndrome; D019851:Thrombophilia / Q000139:chemically induced*
chemical_list: D011372:Progestins